Cytokinetics Inc. Stock
Price
Target price
€31.80
€31.80
0.640%
0.2
0.640%
€78.17
30.07.25 / Tradegate
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cytokinetics Inc. Stock
The Cytokinetics Inc. stock is trending slightly upwards today, with an increase of €0.20 (0.640%) compared to yesterday's price.
With 42 Buy predictions and not a single Sell prediction Cytokinetics Inc. is an absolute favorite of our community.
With a target price of 78 € there is potential for a 145.28% increase which would mean more than doubling the current price of 31.8 € for Cytokinetics Inc..
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | 0.640% | -1.852% | 11.972% | -42.182% | -29.956% | -23.923% | 63.077% |
| Krystal Biotech | 1.900% | 2.919% | 14.824% | -28.571% | -11.958% | 87.413% | - |
| Ardelyx Inc. | 4.440% | 2.121% | 14.166% | -25.441% | -23.384% | 460.153% | -30.202% |
| Evolus Inc | -1.900% | -3.125% | 0.649% | -30.180% | -26.190% | -32.609% | 164.505% |
Comments
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at JPMorgan Chase & Co. from $71.00 to $53.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Mizuho from $103.00 to $84.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
News
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook
Cytokinetics Inc. has recently seen multiple executives selling portions of their stock holdings, all reportedly to cover tax obligations related to Restricted Stock Unit transfers. CEO Robert Blum
